Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02269 WUXI BIO
RTNominal up17.960 +0.220 (+1.240%)
Research Report

05/12/2023 15:33

{I-bank focus}CCB lowers WuXi Bio (02269) to HKD66

[ET Net News Agency, 5 December 2023] CCB International lowered its target price for
WuXi Bio (02269) to HKD66 from HKD77 and maintained its "outperform" rating.
The research house said it lowers FY23 25F sales forecasts by an average of 8.2% each
year to reflect delays recognizing manufacturing revenue from the three blockbuster drugs
and the weaker biotech funding outlook for FY23 24F. (RC)

Back to Research Report

Remark: Real time quote last updated: 17/01/2025 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.